Targeting the Sanctuary Site: Options when Breast Cancer Metastasizes to the Brain

Mridula Krishnan, Jairam Krishnamurthy, Nicole Shonka

Research output: Contribution to journalArticle

Abstract

Brain metastasis is a poor prognostic factor in breast cancer progression, and traditional treatment options have shown minimal response with overall low median survival rates. The incidence of brain metastasis has been increasing despite and, in part, due to advancements in treatment as a result of prolongation of survival. Targeted therapy such anti-HER2 agents have a lower efficacy in this setting compared to metastases elsewhere; however, novel therapies are emerging in this regard. In this comprehensive review, we discuss risk per subtype, special considerations for therapy selection, current focal and systemic treatments, and recent advancements and potential future targets for success. We present our treatment paradigm and multidisciplinary approach to brain metastases arising from breast cancer based on the available evidence, incorporating molecular characteristics.

Original languageEnglish (US)
JournalOncology (Williston Park, N.Y.)
Volume33
Issue number8
StatePublished - Aug 23 2019

Fingerprint

Breast Neoplasms
Neoplasm Metastasis
Brain
Therapeutics
Incidence

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Targeting the Sanctuary Site : Options when Breast Cancer Metastasizes to the Brain. / Krishnan, Mridula; Krishnamurthy, Jairam; Shonka, Nicole.

In: Oncology (Williston Park, N.Y.), Vol. 33, No. 8, 23.08.2019.

Research output: Contribution to journalArticle

@article{240cbf3207f04478b22fb30f58d6b8f6,
title = "Targeting the Sanctuary Site: Options when Breast Cancer Metastasizes to the Brain",
abstract = "Brain metastasis is a poor prognostic factor in breast cancer progression, and traditional treatment options have shown minimal response with overall low median survival rates. The incidence of brain metastasis has been increasing despite and, in part, due to advancements in treatment as a result of prolongation of survival. Targeted therapy such anti-HER2 agents have a lower efficacy in this setting compared to metastases elsewhere; however, novel therapies are emerging in this regard. In this comprehensive review, we discuss risk per subtype, special considerations for therapy selection, current focal and systemic treatments, and recent advancements and potential future targets for success. We present our treatment paradigm and multidisciplinary approach to brain metastases arising from breast cancer based on the available evidence, incorporating molecular characteristics.",
author = "Mridula Krishnan and Jairam Krishnamurthy and Nicole Shonka",
year = "2019",
month = "8",
day = "23",
language = "English (US)",
volume = "33",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "8",

}

TY - JOUR

T1 - Targeting the Sanctuary Site

T2 - Options when Breast Cancer Metastasizes to the Brain

AU - Krishnan, Mridula

AU - Krishnamurthy, Jairam

AU - Shonka, Nicole

PY - 2019/8/23

Y1 - 2019/8/23

N2 - Brain metastasis is a poor prognostic factor in breast cancer progression, and traditional treatment options have shown minimal response with overall low median survival rates. The incidence of brain metastasis has been increasing despite and, in part, due to advancements in treatment as a result of prolongation of survival. Targeted therapy such anti-HER2 agents have a lower efficacy in this setting compared to metastases elsewhere; however, novel therapies are emerging in this regard. In this comprehensive review, we discuss risk per subtype, special considerations for therapy selection, current focal and systemic treatments, and recent advancements and potential future targets for success. We present our treatment paradigm and multidisciplinary approach to brain metastases arising from breast cancer based on the available evidence, incorporating molecular characteristics.

AB - Brain metastasis is a poor prognostic factor in breast cancer progression, and traditional treatment options have shown minimal response with overall low median survival rates. The incidence of brain metastasis has been increasing despite and, in part, due to advancements in treatment as a result of prolongation of survival. Targeted therapy such anti-HER2 agents have a lower efficacy in this setting compared to metastases elsewhere; however, novel therapies are emerging in this regard. In this comprehensive review, we discuss risk per subtype, special considerations for therapy selection, current focal and systemic treatments, and recent advancements and potential future targets for success. We present our treatment paradigm and multidisciplinary approach to brain metastases arising from breast cancer based on the available evidence, incorporating molecular characteristics.

UR - http://www.scopus.com/inward/record.url?scp=85071766498&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071766498&partnerID=8YFLogxK

M3 - Article

C2 - 31469897

AN - SCOPUS:85071766498

VL - 33

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 8

ER -